We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Combined Radiotherapy and Drug Treatment Shown to Improve Survival for Patients with Inoperable Liver Cancer

By MedImaging International staff writers
Posted on 15 Sep 2014
Print article
A study has shown that patients who suffer from inoperable advanced hepatocellular carcinoma (HCC) may have the opportunity to live substantially longer by using a combined therapy.

The multicenter phase II clinical trial conducted by the Asia-Pacific Hepatocellular Carcinoma Trials Group and led by the National Cancer Center Singapore (NCCS) and Singapore General Hospital (SGH) at four Asia Pacific tertiary medical centers evaluated the effectiveness of combining two existing treatment modalities, Sorafenib and selective internal radiation therapy (SIRT). The combination therapy involves starting patients on SIRT using SIR-spheres microspheres, a medical device that contains radioactive microspheres labeled with yttrium-90 for short range, high energy radiation therapy, followed by systemic therapy with an oral chemotherapy drug, Sorafenib, 14 days later.

The mature findings of the trial published March 10, 2014, in the journal PLOS ONE revealed that median overall survival was 20.3 months for patients with intermediate stage HCC and 8.6 months for patients with advanced liver cancer. These final findings were better than the earlier data released in 2010.

Led by Prof. Pierce Chow, a senior consultant surgeon at NCCS and SGH, the investigator-initiated trial, which commenced in June 2008, recruited 29 patients from four countries, namely, Malaysia, Myanmar, Singapore, and the Republic of Korea.

“Hepatocellular carcinoma is the most common type of liver cancer with limited treatment options. About one million individuals are diagnosed with the condition yearly and only 20% of them are eligible for potentially curative treatment. This is a major concern and we aim to change that,” said Prof Chow.

Related Links:

National Cancer Centre Singapore
Singapore General Hospital


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Portable X-Ray Unit
AJEX240H
Compact C-Arm with FPD
Arcovis DRF-C R21
Dose Calibration Electrometer
PC Electrometer

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.